InMed Price Book Value Ratio from 2010 to 2024

INM Stock  USD 4.30  0.23  5.08%   
InMed Pharmaceuticals Price Book Value Ratio yearly trend continues to be very stable with very little volatility. Price Book Value Ratio is likely to drop to -7.61. During the period from 2010 to 2024, InMed Pharmaceuticals Price Book Value Ratio quarterly data regression pattern had range of 562 and standard deviation of  147.98. View All Fundamentals
 
Price Book Value Ratio  
First Reported
2010-12-31
Previous Quarter
4.14453488
Current Value
(7.61)
Quarterly Volatility
147.98290244
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check InMed Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among InMed Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 634.7 K, Interest Expense of 153.3 K or Selling General Administrative of 5.5 B, as well as many indicators such as Price To Sales Ratio of 0.86, Dividend Yield of 0.0 or Days Sales Outstanding of 36.24. InMed financial statements analysis is a perfect complement when working with InMed Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of InMed Pharmaceuticals Correlation against competitors.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.

Latest InMed Pharmaceuticals' Price Book Value Ratio Growth Pattern

Below is the plot of the Price Book Value Ratio of InMed Pharmaceuticals over the last few years. It is InMed Pharmaceuticals' Price Book Value Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in InMed Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Price Book Value Ratio10 Years Trend
Slightly volatile
   Price Book Value Ratio   
       Timeline  

InMed Price Book Value Ratio Regression Statistics

Arithmetic Mean109.99
Coefficient Of Variation134.54
Mean Deviation99.97
Median83.92
Standard Deviation147.98
Sample Variance21,899
Range562
R-Value(0.50)
Mean Square Error17,668
R-Squared0.25
Significance0.06
Slope(16.57)
Total Sum of Squares306,585

InMed Price Book Value Ratio History

2024 -7.61
2023 4.14
2022 3.75
2021 14.52
2020 58.2
2019 157.61
2018 83.92

About InMed Pharmaceuticals Financial Statements

InMed Pharmaceuticals investors utilize fundamental indicators, such as Price Book Value Ratio, to predict how InMed Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Price Book Value Ratio 4.14 (7.61)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether InMed Pharmaceuticals is a strong investment it is important to analyze InMed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact InMed Pharmaceuticals' future performance. For an informed investment choice regarding InMed Stock, refer to the following important reports:
Check out the analysis of InMed Pharmaceuticals Correlation against competitors.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
230.4
Revenue Per Share
0.603
Quarterly Revenue Growth
(0.45)
Return On Assets
(0.39)
Return On Equity
(0.72)
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.